4.6 Article

Analgesic efficacy of systemic lidocaine using lean body mass based dosing regime versus placebo in bariatric surgery: a prospective, randomised, double-blind, placebo-controlled, single-centre study

期刊

BRITISH JOURNAL OF ANAESTHESIA
卷 131, 期 1, 页码 122-129

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.bja.2023.03.027

关键词

bariatric surgery; lidocaine; perioperative analgesia; perioperative opioids; postoperative recovery; post-operative nausea and vomiting

向作者/读者索取更多资源

This study aimed to investigate the efficacy of 1% lidocaine hydrochloride intravenous injection in obese patients undergoing bariatric surgery. The results showed that lidocaine did not improve postoperative pain scores, analgesia, or any secondary outcomes.
Background: Intravenous lidocaine is used as an adjuvant analgesic agent in perioperative settings. It has been inves-tigated in various patient populations and surgical interventions, but there are limited data on its efficacy, particularly for patients undergoing bariatric surgery. Obese patients are at high risk of postoperative respiratory complications and can be expected to benefit from anaesthetic techniques that minimise opioid administration. Methods: We studied administration of lidocaine hydrochloride 1% i.v. to general anaesthesia at a dose of 1.5 mg kg -1 (lean body massx1.28) or placebo in patients undergoing bariatric surgery. Subjects randomly assigned to each group were surveyed for 48 h after surgery for experienced pain (primary outcome), and administered opioids, postoperative nausea and vomiting (PONV), resumption of bowel function, and length of hospital stay (secondary outcomes).Results: We recruited and randomised 140 subjects to either the lidocaine or placebo group; 137 completed the study. Subjects with pain numeric rating scale (NRS) >3 within the first 4 h postoperatively were similar in both groups (pro-portion of any NRS >3 within first 4 h lidocaine group: 47/68 (69%) vs placebo group: 44/69 (63%), P=0.507; within first h P=0.177, within second h P=0.513, within third h P=0.145, within fourth h P=0.510). There was no difference in maximal pain score, opioid consumption, recovery of bowel function, incidence of PONV, or length of hospital stay.Conclusions: Lidocaine does not improve postoperative pain scores, analgesia, or any secondary outcomes in patients undergoing bariatric surgery. Clinical trial registration: NCT03667001.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据